Bayer slides on €9.5bn loss caused by litigation, COVID-19 impactBayer counted the cost of its expensive Roundup weedkiller settlement in the second quarter with a €9.5 billion Share XBayer slides on €9.5bn loss caused by litigation, COVID-19 impacthttps://pharmaphorum.com/news/bayer-slides-on-e9-5bn-loss-caused-by-litigation-covid-19-impact/
Roche’s NTRK tumour-agnostic therapy Rozlytrek approved in EuropeRoche’s tumour-agnostic therapy Rozlytrek has been approved in the European Union for people with tumours with the NTRK Share XRoche’s NTRK tumour-agnostic therapy Rozlytrek approved in Europehttps://pharmaphorum.com/news/roches-tumour-agnostic-therapy-approved-in-europe/
FDA grants fast review for Bayer/Merck & Co’s heart failure drugThe FDA has granted a faster Priority Review for Bayer and Merck & Co’s filing for vericiguat, which is being Share XFDA grants fast review for Bayer/Merck & Co’s heart failure drughttps://pharmaphorum.com/news/fda-grants-fast-review-for-bayer-merck-cos-heart-failure-drug/
Applying digital health to systemic healthcare challengesThe de-prioritisation of face-to-face interactions between patients and healthcare professionals in the wake of COVID-19’s current emergency has Share XApplying digital health to systemic healthcare challengeshttps://pharmaphorum.com/views-analysis-digital/applying-digital-health-to-systemic-healthcare-challenges/
Bayer agrees $10 billion-plus deal to settle Roundup cancer claimsGerman pharma and chemicals group Bayer may finally have put long-running litigation over its weedkiller Roundup in its Share XBayer agrees $10 billion-plus deal to settle Roundup cancer claimshttps://pharmaphorum.com/news/bayer-agrees-10-billion-plus-deal-to-settle-roundup-cancer-claims/
NICE green lights Roche’s Rozlytrek for NTRK tumoursThe UK’s National Institute for Health and Care Excellence (NICE) has cleared Roche’s Rozlytrek for NTRK fusion-positive solid Share XNICE green lights Roche’s Rozlytrek for NTRK tumourshttps://pharmaphorum.com/news/nice-green-lights-roches-rozlytrek-for-ntrk-tumours/
Merck KGaA’s ATR cancer drug cleared for further trials after phase 1 trial successMerck KGaA’s ATR inhibitor cancer drug has been cleared for further clinical trials after it showed encouraging activity in Share XMerck KGaA’s ATR cancer drug cleared for further trials after phase 1 trial successhttps://pharmaphorum.com/news/mercks-atr-cancer-drug-cleared-for-clinical-trials-after-phase-1-trial-success/
After Celgene deal, BMS shoots up pharma market cap rankingsBristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies Share XAfter Celgene deal, BMS shoots up pharma market cap rankingshttps://pharmaphorum.com/news/after-celgene-deal-bms-shoots-up-pharma-market-cap-rankings/
Digital health predicted as the new normal in COVID aftermathThere are few countries left unaffected by COVID-19 and solutions can’t seem to arrive soon enough. In the Share XDigital health predicted as the new normal in COVID aftermathhttps://pharmaphorum.com/views-analysis-digital/digital-health-predicted-as-the-new-normal-in-covid-aftermath/
